相似文献
1
Immune regulation by CD52-expressing CD4 T cells.
Cell Mol Immunol. 2013 Sep;10(5):379-82. doi: 10.1038/cmi.2013.35. Epub 2013 Aug 12.
2
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.
Nat Immunol. 2013 Jul;14(7):741-8. doi: 10.1038/ni.2610. Epub 2013 May 19.
3
Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes.
Int Immunol. 1995 Jan;7(1):69-77. doi: 10.1093/intimm/7.1.69.
4
Regulation unmasked by activation.
Nat Immunol. 2013 Jul;14(7):696-7. doi: 10.1038/ni.2646.
5
Siglec-10 expression is up-regulated in activated human CD4 T cells.
Hum Immunol. 2020 Feb-Mar;81(2-3):101-104. doi: 10.1016/j.humimm.2020.01.009. Epub 2020 Feb 9.
6
CD52 as both a marker and an effector molecule of T cells with regulatory action: Identification of novel regulatory T cells.
Cell Mol Immunol. 2013 Nov;10(6):456-8. doi: 10.1038/cmi.2013.38. Epub 2013 Sep 16.
7
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
Blood. 2005 Mar 15;105(6):2473-9. doi: 10.1182/blood-2004-07-2527. Epub 2004 Nov 30.
8
Altered proximal T-cell receptor signalling events in mouse CD4+ T cells in the presence of anti-CD4 monoclonal antibodies: evidence for reduced phosphorylation of Zap-70 and LAT.
Scand J Immunol. 2003 Apr;57(4):333-41. doi: 10.1046/j.1365-3083.2003.01241.x.
9
CD52 glycan binds the proinflammatory B box of HMGB1 to engage the Siglec-10 receptor and suppress human T cell function.
Proc Natl Acad Sci U S A. 2018 Jul 24;115(30):7783-7788. doi: 10.1073/pnas.1722056115. Epub 2018 Jul 11.
10
CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.
Clin Immunol. 2006 Sep;120(3):247-59. doi: 10.1016/j.clim.2006.05.006. Epub 2006 Jun 22.
引用本文的文献
1
Single cell analysis identifies distinct CD4 + T cells associated with the pathobiology of pediatric obesity related asthma.
Sci Rep. 2025 Feb 26;15(1):6844. doi: 10.1038/s41598-025-88423-4.
2
Glycosylation in the tumor immune response: the bitter side of sweetness.
Acta Biochim Biophys Sin (Shanghai). 2024 Jun 28;56(8):1184-1198. doi: 10.3724/abbs.2024107.
3
Xist ribonucleoproteins promote female sex-biased autoimmunity.
Cell. 2024 Feb 1;187(3):733-749.e16. doi: 10.1016/j.cell.2023.12.037.
4
Identification of potential diagnostic biomarkers of atherosclerosis based on bioinformatics strategy.
BMC Med Genomics. 2023 May 12;16(1):100. doi: 10.1186/s12920-023-01531-w.
5
The meningeal transcriptional response to traumatic brain injury and aging.
Elife. 2023 Jan 3;12:e81154. doi: 10.7554/eLife.81154.
6
Long-Term Elevated Siglec-10 in Cerebral Spinal Fluid Heralds Better Prognosis for Patients with Aneurysmal Subarachnoid Hemorrhage.
Dis Markers. 2022 Sep 21;2022:5382100. doi: 10.1155/2022/5382100. eCollection 2022.
7
Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era.
Immunotargets Ther. 2021 Jul 7;10:237-246. doi: 10.2147/ITT.S240890. eCollection 2021.
8
Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis.
J Pers Med. 2021 Apr 23;11(5):335. doi: 10.3390/jpm11050335.
9
A signature of estimate-stromal-immune score-based genes associated with the prognosis of lung adenocarcinoma.
Transl Lung Cancer Res. 2021 Mar;10(3):1484-1500. doi: 10.21037/tlcr-21-223.
10
High expression of CD52 in adipocytes: a potential therapeutic target for obesity with type 2 diabetes.
Aging (Albany NY). 2021 Mar 11;13(8):11043-11060. doi: 10.18632/aging.202714.
本文引用的文献
1
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.
Nat Immunol. 2013 Jul;14(7):741-8. doi: 10.1038/ni.2610. Epub 2013 May 19.
2
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells.
Nat Med. 2013 Jun;19(6):739-46. doi: 10.1038/nm.3179. Epub 2013 Apr 28.
3
Development and maintenance of regulatory T cells.
Immunity. 2013 Mar 21;38(3):414-23. doi: 10.1016/j.immuni.2013.03.002.
4
Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS.
Nat Rev Neurol. 2013 Mar;9(3):125-6. doi: 10.1038/nrneurol.2013.2. Epub 2013 Jan 29.
5
Alemtuzumab for multiple sclerosis: a new age of immunotherapy.
J Neurol. 2013 Jan;260(1):343-5. doi: 10.1007/s00415-012-6786-x.
6
Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis.
Circulation. 2012 Sep 4;126(10):1256-66. doi: 10.1161/CIRCULATIONAHA.112.099044. Epub 2012 Jul 31.
7
Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis.
Expert Rev Neurother. 2012 Mar;12(3):335-41. doi: 10.1586/ern.12.5.
8
Siglecs and immune regulation.
Annu Rev Immunol. 2012;30:357-92. doi: 10.1146/annurev-immunol-020711-075018. Epub 2012 Jan 3.
9
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort.
Neurology. 2011 Aug 9;77(6):573-9. doi: 10.1212/WNL.0b013e318228bec5. Epub 2011 Jul 27.
10
Expression of TNFRSF25 on conventional T cells and Tregs.
J Clin Invest. 2011 Feb;121(2):463-4; author reply 465. doi: 10.1172/JCI45832. Epub 2011 Feb 1.
Zotero 插件